ALIPANC

Pancreatic cancer

Pancreatic cancer is one of the most aggressive tumors and, despite its relatively low incidence, it ranks very high in terms of mortality. In Spain, 8,211 pancreatic cancer patients were diagnosed in 2020 and 7,568 died in the same year. When a patient is diagnosed with pancreatic cancer, he loses 98% of his life expectancy because the average survival is still about 7 months, with only 7% of patients surviving 5 years after diagnosis. Although increasingly effective treatments exist, very few patients are able to benefit from them since the majority (80%) of patients are diagnosed when the tumor is already in advanced stages. Moreover, the fact that its frequency is increasing significantly in our environment is going to make this tumor a relevant public health problem if measures are not taken quickly.

The little interest it has generated so far in society due to its lack of knowledge, in medical and research circles due to the limited availability of options for the management of these patients and the difficulties in researching this cancer, and in funding agencies due to its low incidence and prevalence, has meant that there have been no significant advances in controlling this disease compared to other cancers that are currently preventable and curable, such as breast cancer. All this explains why pancreatic cancer is out of control.

The Alliance for Research on Pancreatic Cancer in Spain (ALIPANC) is a platform of researchers who join forces and resources to carry out high quality multicenter and multidisciplinary studies on this cancer with the ultimate goal of reducing its incidence and mortality and improving the survival of patients suffering from it.